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Abstract
Protamine, the only registered antidote of unfractionated heparin (UFH), may produce a
number of adverse effects, such as anaphylactic shock or serious hypotension. We aimed
to develop an alternative UFH antidote as efficient as protamine, but safer and easier to pro-
duce. As a starting material, we have chosen generally non-toxic, biocompatible, widely
available, inexpensive, and easy to functionalize polysaccharides. Our approach was to
synthesize, purify and characterize cationic derivatives of dextran, hydroxypropylcellulose,
pullulan and γ-cyclodextrin, then to screen them for potential heparin-reversal activity using
an in vitro assay and finally examine efficacy and safety of the most active polymers in Wis-
tar rat and BALB/c mouse models of experimentally induced arterial and venous thrombo-
sis. Efficacy studies included the measurement of thrombus formation, activated partial
thromboplastin time, bleeding time, and anti-factor Xa activity; safety studies included the
measurement of hemodynamic, hematologic and immunologic parameters. Linear, high
molecular weight dextran substituted with glycidyltrimethylammonium chloride groups at a
ratio of 0.65 per glucose unit (Dex40-GTMAC3) is the most potent and the safest UFH inhib-
itor showing activity comparable to that of protamine while possessing lower immunogenici-
ty. Cationic polysaccharides of various structures neutralize UFH. Dex40-GTMAC3 is a
promising and potentially better UFH antidote than protamine.
Introduction
Although many new antithrombotic agents were introduced in the last few years, unfractio-
nated heparin (UFH), an anionic polysaccharide, remains a key drug inhibiting blood coagula-
tion in case of emergency. It enables open-heart surgery by preventing blood clotting in the
heart-lung machine (cardiopulmonary bypass) oxygenating and supplying blood to the main
body organs. After surgery almost all patients have to receive protamine: a cationic protein
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inactivating heparin and restoring coagulation; most would probably bleed to death without
this antidote [1].
Kimmel et al. [2] predicted that 7% of these patients may die anyway because of serious side
effects of protamine, such as anaphylactic shock, pulmonary vasoconstriction or systemic hy-
potension [3–6]. According to reports the incidence of protamine-related anaphylaxis varies
from 0.2 to 10% [4,6]. In 2003 666,000 open-heart surgeries and 470,000 Coronary Artery By-
pass Graft (CABG) procedures were performed within the USA [7]. Although in 2010 these
numbers decreased by 15% due to more frequent percutaneous interventions [8], protamine
usage increased in vascular surgery, such as fistula placement, abdominal aortic aneurysm re-
pair, and other open abdominal surgeries, or transcatheter aortic valve implantations [9].
Thus, in the USA alone more than one thousand life-threatening complications a year could be
attributed to the toxicity of protamine [8]. Allergy to fish may predispose to this acute re-
sponse, because commercial protamine originates from sperm of salmon fished around Japan
[10]. Since protamine is also used to slow down absorption and to prolong action of some insu-
lins, diabetic patients might be prone to fatal allergic reactions [10,11]. European Medicines
Agency alerted about potential supply shortage of protamine after Fukushima nuclear plant di-
saster. Obviously, because of the problematic supply source of protamine and safety reasons, a
new heparin antidote is strongly desired. The quest for a safer alternative to protamine has a
long history and has been exhaustively described in a recent review [12]. So far the pharmaceu-
tical companies have suspended the development of a number of UFH antidotes, for example
L-lysine [13], due to expensive large-scale synthesis. Thus, as a starting material for the synthe-
sis of cationic polymers, we chose generally non-toxic, biocompatible, widely available, inex-
pensive, and easy to functionalize polysaccharides. We had previously explored the mechanism
of UFH binding by modified polysaccharides such as chitosan [14,15], dextran [16,17], and
hydroxypropylcellulose [16]. Their cationic groups attached to the polysaccharide chain bind
to the anionic groups attached to the UFH chain and form inactive polycation-UFH complex.
In the present study we aimed to develop a new UFH antidote with full inhibitory potency,
but safer and easier to produce than protamine. First, our team—consisting of chemists, phar-
macologists and immunologists—synthesized and characterized several positively-charged
polymers, whose structure, like that of heparin, is based on a polysaccharide main chain. The
novel molecules originated from dextran, hydroxypropylcellulose, pullulan or γ-cyclodextrin
and differed in the molecular weight, architecture and cationic charge density. Then, based on
in vitro UFH binding assay we selected the most promising polymers and, finally, we compared
the efficacy and safety of the most active agents in the animal models of thrombosis. We select-
ed the most potent and safe heparin antidote using rat model of electrically-induced arterial
thrombosis [18], which we found previously to be suitable for testing antithrombotic and antic-
oagulative effects of various agents [17,19–24]. We also evaluated immunogenic properties of
selected novel polymers and compared them with protamine in a repeated-dose animal study.
Materials and Methods
Animals
Animals were purchased from and housed in the Centre of Experimental Medicine of Medical
University of Bialystok in specific pathogen free conditions according to Good Laboratory
Practice rules. 166 male Wistar rats and 45 BALB/c mice were used in all experiments. Animals
were housed with a 12 h light/dark cycle in temperature (22 ± 2°C) and humidity (55 ± 5%)
controlled room, grouped cages as appropriate, and allowed to have ad libitum access to steril-
ized tap water and a standard chow (Ssniff R-Z V1324). The animals’ health status was moni-
tored throughout the experiments by a health surveillance programme according to Federation
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of European Laboratory Animal Science Associations (FELASA) guidelines. The rats and mice
were free of all viral, bacterial, and parasitic pathogens listed in the FELASA recommendations.
All the procedures involving animals and their care were approved by Local Ethical Committee
on Animal Testing at the Medical University of Bialystok (Permit Numbers 28/2012 and 15/
2013) and by First Local Ethical Committee on Animal Testing at the Jagiellonian University
in Krakow (Permit Number 92/2012) and conducted in accordance with ARRIVE guidelines
[25], directive 2010/63/EU of the European Parliament and of the Council on the protection of
animals used for scientific purposes and the national laws. Procedures were conducted in the
light phase of cycle in the surgical room of our laboratory. All animals were euthanized by ex-
sanguination at the end of experiments.
Chemicals and drugs
Dextran (Dex40, Mw = 40 kDa from Leuconostoc spp.; Dex6, Mw = 6 kDa from Leuconostoc
spp.), hydroxypropylcellulose (HPC, Mn 10 kDa, Mw 80 kDa), pullulan (Pul, 200 kDa, from
Aureobasidium pullulans), γ-cyclodextrin (GCD,90.0% cyclodextrin basis (HPLC),
N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride (EDC,99.0%), N-hydro-
xysuccinimide (NHS, 98%), L-arginine (reagent grade,98% TLC), allylamine (99%), sper-
mine (Spm,>97%), 2,20-azobis(2-methylpropionamidine) dihydrochloride (AAPH, 97%), N,
N'-carbonyldiimidazole (CDI, reagent grade), N-acrylamidopropyl-N,N,N-trimethylammo-
nium chloride (APTMAC, 75 wt% solution in water, stabilized with 3000 ppmMEHQ), glyci-
dyltrimethylammonium chloride (GTMAC, technical90%), benzoyl peroxide (BPO, 75%
remainder water Luperox A75), heparin sodium salt from bovine intestinal mucosa (UFH),
protamine (protamine sulfate salt from salmon, grade X), N,N-dimethylformamide (DMF, an-
alytical grade), dimethyl sulfoxide (DMSO, analytical grade), trisodium citrate (99%) were
purchased from Sigma-Aldrich (Germany). Dex1 (Mw = 1 kDa from Leuconostoc spp.) was
purchased from Pharmacosmos (Denmark). Azure A chloride (Fluka standard) was purchased
from Fluka (Switzerland). Acetone, ethanol 96%, methanol, potassium chloride, potassium
dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, NaOH, were all ana-
lytical grade and purchased from POCh (Poland). Routine laboratory reagents to determine ac-
tivated partial thromboplastin time (aPTT) in plasma were purchased from Bio-Ksel (Poland).
Anti-Xa assay kits were purchased from Sekisui Diagnostics (USA). Pentobarbital, ketamine,
and xylazine were purchased from Biovet (Poland).
Polymer synthesis and characteristics
Polysaccharides substituted with GTMAC were synthesized using the general procedure de-
scribed previously [16]. All the details of polymers synthesis and solubility are presented in S1
File. UV-Vis absorption spectra were recorded using an HP8452A diode-array spectrophotom-
eter in 1-cm optical path quartz cells. The dimensions of the aggregates in aqueous suspensions
were determined using Malvern Instruments Ltd Nano ZetaSizer. FTIR spectra were obtained
using a Bruker IFS 48 spectrometer. NMR spectra were measured in D2O using a Bruker AMX
500 spectrometer. GPC analyses were performed using a Waters GPC system equipped with a
bank of three columns (PL Aquagel-OH 30, 40, and 60) and tandem PDA/RI detectors. The el-
uent was 0.1 M NaCl, flow rate was 0.6 mlmin-1, sample volume was 150 μl, and the concen-
tration of polymers was 5 gl-1.
Binding of UFH by the cationic polymers
The ability of the studied substances to bind UFH was assessed with a colorimetric method
using Azure A, a cationic dye, as described previously [14,15]. Briefly, UFH chains, when
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present in the solution of Azure A, complex the dye molecules, which then form aggregates ab-
sorbing at 513 nm, while the monomeric form of the dye (in the absence of UFH) absorbs at
630 nm. Added polymer disrupts dye aggregates partially (or fully in the case of complete bind-
ing of UFH) and increases 630 nm and decreases 513 nm absorption band intensity. A repre-
sentative example of the plot showing the dependence of free (i.e., uncomplexed and therefore
possessing anticoagulant activity) UFH concentration on the cationic polymer concentration,
expressed as the ratio of the cationic polymer mass and total UFH mass, is shown in Fig. 1.
Experimental arterial thrombosis in rats
84 male Wistar rats weighing 216 ± 10.8 g (no significant difference between groups) were ran-
domly divided into 10 groups (8–10 per experimental group), anesthetized by an intraperitone-
al injection of pentobarbital (45 mgkg-1 b.w.) and placed in a supine position on a heated
operation table. UFH was administered into right femoral vein in a volume not exceeding 0.5
mlkg-1 b.w. 10 min before the induction of thrombosis in dose of 300 Ukg-1 b.w. alone or fol-
lowed (3 min) by intravenous (iv) administration of Dex40-GTMAC2 (4.2 mgkg-1 b.w.),
Dex40-GTMAC3 (2.5 and 7.5 mgkg-1 b.w.), Dex6-GTMAC (9.6 mgkg-1 b.w.),
GCD-GTMAC2 (10.8 mgkg-1 b.w.), or protamine (3 mgkg-1 b.w.). Vehicle (PBS) treated ani-
mals served as a control group. Additionally, UFH was administered into right femoral vein of
16 male Wistar rats, weighing 209.7 ± 9.9 g in dose of 900 Ukg-1 b.w. alone or followed by iv
administration of Dex40-GTMAC3 (22.5 mgkg-1 b.w.). Dex40-GTMAC3 was also adminis-
tered alone in dose of 7.5 mgkg-1 b.w. Arterial thrombosis was induced by electrical
Fig 1. Binding of UFH by the cationic polymers.Dependence of free UFH concentration on the concentration of Dex6-GTMAC expressed as the ratio of
the Dex6-GTMACmass and total UFHmass. Data for protamine are shown for comparison.
doi:10.1371/journal.pone.0119486.g001
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stimulation of the common carotid artery, according to methods previously described [18,26].
Briefly, the anode, a stainless steel L-shaped wire, was inserted under the artery and connected
to a circuit with a constant current generator. The cathode was a subcutaneous metal needle at-
tached to the hindlimb. The stimulation (1 mA) took 10 min. 45 min after stimulation the seg-
ment of the common carotid artery with the formed thrombus was clipped at both sides,
dissected opened lengthwise and the thrombus was completely removed, air-dried in 37°C and
weighed 24 h after the end of experiment. Thrombus weight was our primary endpoint, whereas
coagulation markers measured in plasma served as secondary endpoints. After removal of
formed thrombus blood samples were taken from the heart. The blood samples were drawn
into 3.13% trisodium citrate in a volume ratio of 9:1, then centrifuged at 3500 x g at 4°C for 20
min and plasma was deep-frozen (-70°C) in aliquots of 1 ml until further assays could be per-
formed. A time-line diagram of this experiment was presented in our previous publication [17].
Experimental venous thrombosis in mice
25 male BALB/c mice weighing 24.2 ± 0.2 g (no significant difference between groups) and
aged 8–10 weeks were randomly divided into 4 groups (5–7 per experimental group). Animals
were anesthetized with a mixture of ketamine (125 mgkg-1 b.w.) and xylazine (12.5 mgkg-1 b.
w.). After the anesthesia animals were heparinized with 300 Ukg-1 b.w. (50 μl iv into tail vein).
Three minutes after injection, UFH was neutralized with protamine (3 mgkg-1 b.w.) or
Dex40-GTMAC3 (7.5 mgkg-1 b.w.). The Electrolytic Inferior Vena Cava Model was performed
as previously described [27]. Briefly, the abdomen was opened, and all inferior vena cava side
branches were carefully ligated. The 25G stainless-steel needle was inserted into the exposed
caudal vena cava and connected to a current source of 25 μA over 15 minutes (anode). After 15
minutes the needle was removed and abdomen was closed in a two-layer fashion. After six
hours the animals were reanesthetized and the abdomen was reopened, the vena cava was care-
fully dissected and inspected for the presence of thrombus. The thrombus was kept at 37°C and
after 24 hours its dry weight was measured.
Bleeding time in rats
The tail bleeding time was measured after removal of formed thrombus using a standardized
Simplate device (Simplate II, Organon Teknika Corp., USA). The device makes two incisions 5
mm long and 1 mm deep on the dorsal part of the tail between 9 and 11 cm from the tip, taking
care to avoid large veins. Immediately after injury, the tail was placed into the cylinder with iso-
tonic saline at 37°C. Bleeding time was measured from the moment the tail was surgically cut
until bleeding stopped completely (no rebleeding within 30 s). If bleeding was still present at
the end of the 300 s observation period, a value of 300 s was ascribed for the sake of statistical
analysis. Bleeding time was expressed in seconds.
aPTT measurement in rats and mice
The aPTT was measured in plasma collected from thrombotic rats or mice as a basic coagula-
tion parameter used for monitoring of UFH action. Additionally, Dex40-GTMAC3 was as-
sayed for potential anticoagulant activity by measuring of aPTT according to a modified
procedure of Byun et al. [28]. The blood samples were taken from the heart of 5 male Wistar
rats, and were drawn into 3.13% trisodium citrate in a volume ratio of 9:1, then centrifuged at
3500 × g at 4°C for 20 min and 200 μl of pooled plasma was mixed with 20 μl of a solution con-
taining increasing concentrations of Dex40-GTMAC3. The aPTT values were automatically
determined with an optical method (Coag-Chrom 3003; Bio-ksel, Poland) adding routine labo-
ratory reagents to collected animal plasma.
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Anti-factor Xa activity in rats
Anti-factor Xa activity was analyzed with ELISA technique at 25°C using a microplate reader
(Dynex Tech., USA) according to the kit manufacturer instructions.
Blood cell count in rats
Blood cell count was assessed with an Animal Blood Counter (ABC Vet, Horiba, Germany) ac-
cording to the manufacturer directions.
Blood pressure measurement in rats
The mean blood pressure (MBP) was measured directly through a cannula filled with UFH so-
lution (150 Uml-1), placed in the left common carotid artery and connected to the pressure
transducer (Plugsys, Transonics System, USA) in anaesthetized Wistar rats weighing
239.7 ± 7.2 g (no significant difference between groups), as described previously [29]. 74 Wistar
rats were randomly divided into 16 groups (4–6 per experimental group). The schedule of drug
administration was the same as in arterial thrombosis experiment. Additionally, polymers were
administered alone in 3 times higher doses.
Immunization experiments
20 female BALB/c mice weighing 26.3 ± 0.5 g (no significant difference between groups) and
aged 8–10 weeks were randomly divided into 4 groups (5 per experimental group). Animals
were anesthetized with a mixture of ketamine (125 mgkg-1 b.w.) and xylazine (12.5 mgkg-1 b.
w.) and were heparinized with 150 Ukg-1 b.w. (50 μl iv into tail vein). Three minutes after in-
jection, UFH was neutralized with protamine (1.5 mgkg-1 b.w.), or Dex40-GTMAC2 (6.25
mgkg-1 b.w.), or Dex40-GTMAC3 (3.75 mgkg-1 b.w.). All antidotes were injected iv into tail
vein in 50 μl of saline, while the control group (UFH) was not administered any antidote. The
heparinization/neutralization regimen was repeated 5 times, once every week (days 1, 8, 15, 22,
and 29). Blood samples were collected from the tail vein of each mouse one day prior UFH ad-
ministration and serum was isolated by centrifugation. One week after the last injection (day
36) all mice were sacrificed; final blood samples were collected and spleens of the animals were
isolated for evaluation.
Immune response evaluation
The levels of antibodies specific to protamine, Dex40-GTMAC2, and Dex40-GTMAC3 were
evaluated using standard indirect ELISA. Briefly, wells of a 96-well plate (Nunc MaxiSorp)
were coated O/N at RT with 50 μl of antigen solution (25 μgml-1 in PBS). The wells were
blocked O/N with 200 μl of 1% BSA in PBS at 4°C. Serum samples were diluted in PBS, added
to the wells washed with PBS, and incubated O/N at 4°C. Murine antibodies bound to the anti-
gen were detected with horseradish peroxydase-conjugated secondary antibodies specific to
mouse IgM (Sigma A8786, 1:5 000) or mouse IgG (Sigma A3673, 1:10 000). Colorimetric detec-
tion was based on TMB substrate solution (BD Biosciences) and the enzymatic reaction was
stopped by adding 50 μl of 0.18 M H2SO4. ELISA signals were measured at 450 nm using VER-
SAmax microplate reader (Molecular Devices). All sera were tested on each antigen (prot-
amine, Dex40-GTMAC2, and Dex40-GTMAC3) to detect potential cross-reactivity.
Statistical analysis
In the study, n refers to number of animals in each experimental group. For each test, the ex-
perimental unit was an individual animal. We choose the minimal number of animals to detect
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differences between each group basing on our and others experience using these procedures.
The data are shown as mean ± SD and analyzed using the non-parametric Mann-Whitney test.
P values less than 0.05 were considered significant, less than 0.01 highly significant and less
than 0.001 extremely significant.
Results
Characteristics of the synthesized polymers
Table 1 shows characteristics of obtained polymers. Their structure varied in the type of: modi-
fied polysaccharide (Dex 1, 6 or 40 kDA, Pul, HPC or GCD), type of cationic group (GTMAC,
APTMAC, Spm, PAH or PAH-ARG), degree of substitution, and charge expressed as zeta po-
tential. All the details of elemental analysis, 1H nuclear magnetic resonance (NMR) and Fourier
transform infrared (FT-IR) spectroscopy measurements are presented in S2 File.
In vitro UFH binding by the cationic polymers
The concentration of free UFH in the solution decreased with increasing concentration of all
the synthesized polymers, except for Dex1-GTMAC and GCD-GTMAC1. Generally, the poly-
mers with lower degree of substitution with cationic groups bound UFH weaker than prot-
amine i.e., their higher concentration was required to achieve the same decrease in free UFH
concentration. The amount of polymers necessary for binding 90% of 1 mg of UFH was used
Table 1. Characteristics of the polymers.
Polymer MW (kDa)a ξb (mV) Degree of substitutionc UFH bindingd
Dex1-GTMAC 1 - 0.45 no binding
Dex6-GTMAC 6 3.0 ± 0.6 0.59 2.7
Dex40-GTMAC1 40 ~0 0.10 insufficient bindinge
Dex40-GTMAC2 40 1.2 ± 0.4 0.50 2.7
Dex40-GTMAC3 40 3.2 ± 0.6 0.65 1.6
Dex40-APTMAC 40 1.0 ± 0.7 0.42 insufficient bindinge
Dex40-Spm 40 1.9 ± 0.3 0.71 1.0
Dex40-PAH 40 0–2f 1.17 insoluble
Dex40-PAH-Arg 40 1.2 ± 2.8 0.10g 2.2
Pul-GTMAC 200 2.6 ± 0.1 0.71 1.9
GCD-GTMAC1 1.297 - 0.66 no binding
GCD-GTMAC2 1.297 - 0.99 2.8
HPC-APTMAC1 80 2.8 ± 0.2 0.22 insufficient bindinge
HPC-APTMAC2 80 8.5 ± 0.4 4.11 1.0
Dex—dextran, Pul—pullulan, GCD—γ-cyclodextrin, HPC—hydroxypropylcellulose, GTMAC—ammonium group of glycidyltrimethyl-ammonium chloride,
APTMAC—ammonium group of N-acrylamidopropyl-N,N,N-trimethylammonium chloride, Spm—primary and secondary amine groups of N,N0-Bis
(3-aminopropyl)-1,4-diaminobutane (Spermine), PAH—primary amine group of poly(allylamine hydrochloride), PAH-Arg—primary amine group of poly
(allylamine hydrochloride), guanidyl group of arginine,
a MW—weight average molecular weight, for GCD exact molecular weight is given
b ξ—zeta potential
c degree of substitution defined as the number of the cationic groups per a glucose unit, as found from elemental analysis
d UFH binding—ratio of polymer mass to UFH mass required for binding 90% of UFH
e the mass of the polymer required to bind UFH was at least 8 times higher than that of protamine
f depending on concentration
g degree of substitution defined as the number of arginine groups per PAH repeating unit
doi:10.1371/journal.pone.0119486.t001
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as a measure of the binding efficiency. If this value exceeded the analogous value for protamine
more than eight times the compound was disqualified from further biological studies. This
value was also used for the preliminary assessment of the dose of a cationic polymer required
in biological tests.
Reversal of the effects of UFH on the arterial thrombosis in rats
UFH dose dependently decreased the weight of arterial thrombus in rats. Studied agents re-
versed antithrombotic effect of UFH (Fig. 2). The polymers were administered in doses corre-
sponding with the ratio of polymer/UFH estimated in the UFH binding assay.
Dex40-GTMAC3 was the most potent and its effect was comparable to the effect of protamine.
It also reversed the antithrombotic effect of UFH administered in dose of 900 Ukg-1 b.w.
(Fig. 2). Dex40-GTMAC2 administered in dose of 4.2 mgkg-1 b.w. was completely ineffective.
Fig 2. Reversal of the effects of UFH on the arterial thrombosis in rats.Dry thrombus weight in Wistar
rats treated with vehicle (PBS), UFH in dose of 300 or 900 U kg-1) alone or followed by Dex40-GTMAC2 (4.2
mgkg-1), Dex40-GTMAC3 (2.5, 7.5 or 22.5 mgkg-1), Dex6-GTMAC (9.6 mgkg-1), GCD-GTMAC2 (10.8
mgkg-1), and protamine (3.0 mgkg-1), c-P<0.001 vs. vehicle; d-P<0.05, e-P<0.01 vs. UFH 300 Ukg-1; l-
P<0.001 vs. UFH 900 Ukg-1, Mann-Whitney test. Results are shown as mean ± SD, n = 8–10.
doi:10.1371/journal.pone.0119486.g002
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When administered alone Dex40-GTMAC3 did not influence thrombus weight (0.98 ± 0.25
mg) in comparison to control group (0.92 ± 0.17 mg).
Reversal of the effects of UFH on the venous thrombosis in mice
Similarly to the results in the model of the arterial thrombosis in rats, UFH significantly de-
creased thrombus weight and prolonged aPTT in mice developing electrically induced venous
thrombosis. We confirmed the ability of Dex40-GTMAC3 to reverse antithrombotic and anti-
coagulant effects of UFH in mice (Fig. 3).
Influence of the cationic polymers on aPTT
In vivo, Dex40-GTMAC3, Dex6-GTMAC, GCD-GTMAC1, and protamine significantly short-
ened aPTT which was prolonged by earlier administration of UFH. We found that the effect of
GCD-GTMAC2 was the weakest, whereas Dex40-GTMAC3 and protamine completely re-
versed the effects of UFH to the control value (Fig. 4). Dex40-GTMAC3 reversed also aPTT
prolonged by 900 Ukg-1 b.w. of UFH, and when administered alone slightly (by 30%), but sig-
nificantly prolonged aPTT to 26.28 ± 6.94 seconds in comparison to 20.28 ± 1.08 seconds in
control group (P<0.01).
Fig 3. Reversal of the effects of UFH on the venous thrombosis and aPTT in mice.Dry thrombus weight
(A) and the aPTT (B) in mice treated with vehicle (PBS), UFH (300 Ukg-1) alone or followed by
Dex40-GTMAC3 (7.5 mgkg-1), and protamine (3.0 mgkg-1), b-P<0.01, c-P<0.001 vs. vehicle; e-P<0.01 vs.
UFH 300 Ukg-1; h-P<0.01 vs. UFH 300 Ukg-1 + Protamine 3.0 mgkg-1, Mann-Whitney test. Results are
shown as mean ± SD n = 5–7.
doi:10.1371/journal.pone.0119486.g003
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Fig 4. Influence of the cationic polymers on aPTT in rats. aPTT in Wistar rats treated with vehicle (PBS), UFH (300 Ukg-1) alone or followed by
Dex40-GTMAC2 (4.2 mgkg-1), Dex40-GTMAC3 (2.5 and 7.5 mgkg-1), Dex6-GTMAC (9.6 mgkg-1), GCD-GTMAC2 (10.8 mgkg-1), and protamine (3.0
mgkg-1), c-P<0.001 vs. vehicle; f-P<0.001 vs. UFH 300 Ukg-1; i-P<0.001 vs. UFH 300 Ukg-1 + Protamine 3.0 mgkg-1; l-P<0.001 vs. UFH 900 Ukg-1,
Mann-Whitney test. Results are shown as mean ± SD, n = 8–10.
doi:10.1371/journal.pone.0119486.g004
Polysaccharide Antidotes for Heparin
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In vitro, Dex40-GTMAC3 prolonged aPTT at higher concentration than 50 mgl-1 (Fig. 5).
Reversal of tail bleeding time by the cationic polymers
Similarly to aPTT measurement, UFH prolonged the tail transection bleeding time. Dex40-GT-
MAC3 in the dose of 2.5 mgkg-1 b.w., Dex6-GTMAC and GCD-GTMAC2 partially but signif-
icantly shortened bleeding time prolonged by 300 Ukg-1 b.w. of UFH (Fig. 6). When
administered in the ratio of 2.5 mg for every 100 Ukg-1 b.w of UFH, Dex40-GTMAC3
completely reversed tail bleeding time prolonged by 300 or 900 Ukg-1 b.w of UFH to the con-
trol value (Fig. 6). Dex40-GTMAC3 administered alone did influence bleeding time
(111.3 ± 18.9 sec.) in comparison to vehicle (104.3 ± 4.6 sec.).
Reversal of plasma anti-Xa activity by the cationic polymers
Dex40-GTMAC3 and protamine significantly reversed increase of anti-Xa activity in UFH-
treated animals (Fig. 7). Other polymers were completely or partially ineffective.
Blood count
UFH significantly increased white blood cells (WBC). This increase of WBC was completely re-
versed to control value by protamine injection. All modified polymers partially, but significant-
ly, inhibited increase of WBC in UFH treated animals. Only Dex40-GTMAC3 did not change
any other blood count. GCD-GTMAC2 significantly changed red blood cell count, hemoglo-
bin, and hematocrit values. All results are presented in Table 2.
Fig 5. aPTT in plasma of Wistar rats mixed with different concentrations of Dex40-GTMAC. a-P<0.05,
b-P<0.01 vs. vehicle, Mann-Whitney test. Results are shown as mean ± SD, n = 5.
doi:10.1371/journal.pone.0119486.g005
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Effects of the cationic polymers on blood pressure in rats
MBP courses in rats one hour after administration of the polymers and protamine are pre-
sented in Fig. A and B in S3 File. The maximum magnitude of MBP change is shown in
Fig. 8A. MBP decreased in groups treated with modified Dex and protamine whereas it in-
creased in animals treated with cationic GCD. In the group treated with Dex40-GTMAC2
MBP decreased by almost half in 15th minute if the polymer was injected alone in the dose that
efficiently reversed previous anticoagulant effects of UFH. We also found significant, but much
weaker and temporary change of MBP shortly after administration of Dex40-GTMAC3
Fig 6. Reversal of tail bleeding time by the cationic polymers. Tail bleeding time in Wistar rats treated with vehicle (PBS), UFH in dose of 300 or 900
Ukg-1 alone or followed by Dex40-GTMAC2 (4.2 mgkg-1), Dex40-GTMAC3 (2.5, 7.5 or 22.5 mgkg-1), Dex6-GTMAC (9.6 mgkg-1), GCD-GTMAC2 (10.8
mgkg-1), and protamine (3.0 mgkg-1), c-P<0.001 vs. vehicle; e-P<0.01, f-P<0.001 vs. UFH 300 Ukg-1; h-P<0.01, i-P<0.001 vs. UFH 300 Ukg-1
+ Protamine 3.0 mgkg-1; l-P<0.001 vs. UFH 900 Ukg-1, Mann-Whitney test. Results are shown as mean ± SD, n = 8–10.
doi:10.1371/journal.pone.0119486.g006
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(decrease in MBP) and GCD-GTMAC2 (increase in MBP). Further increasing of the doses re-
sulted in sustained significant drop in MBP in all animals including protamine treated group.
If UFH was injected 3 minutes before the administration of the cationic polymers, only
Dex40-GTMAC2 and Dex6-GTMAC decreased MBP by 13 and 11%, respectively, whereas
Dex40-GTMAC3 and protamine did not (Fig. 8B). One polymer (Dex40-PAH-Arg) was ex-
tremely hypotensive, and three others (Dex40-Spm, Pul-GTMAC and HPC-APTMAC2) were
lethal. Thus, we discontinued studying of these polymers. The results of experiment preformed
in one rat are presented in Fig. C in S3 File.
Evaluation of the immune response to the cationic polymers
Since no control antibodies specific to protamine, Dex40-GTMAC2, and Dex40-GTMAC3
were available, antigen coating in ELISA was confirmed with spectroscopic and colorimetric
methods. Both early (IgM-class) and mature (IgG-class) phases of humoral immune response
were evaluated. No IgM antibodies specific to any of the antigens were detected. Given low
Fig 7. Reversal of plasma anti-fXa activity by the cationic polymers. Anti-fXa activity in Wistar rats
treated with vehicle (PBS), UFH (300 Ukg-1) alone or followed by Dex40-GTMAC2 (4.2 mgkg-1),
Dex40-GTMAC3 (2.5 and 7.5 mgkg-1), Dex6-GTMAC (9.6 mgkg-1), GCD-GTMAC2 (10.8 mgkg-1), and
protamine (3.0 mgkg-1), c-P<0.001 vs. vehicle; f-P<0.001 vs. UFH 300 Ukg-1; i-P<0.001 vs. UFH 300 Ukg-
1 + Protamine 3.0 mgkg-1, Mann-Whitney test. Results are shown as mean ± SD, n = 8–10.
doi:10.1371/journal.pone.0119486.g007
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Fig 8. Effects of the cationic polymers on blood pressure in rats.MBP change registered 60 min after iv administration of Dex40-GTMAC2 (4.2 and 12.5
mgkg-1), Dex40-GTMAC3 (2.5, 7.5, and 22.5 mgkg-1), Dex6-GTMAC (9.6 and 28.8 mgkg-1), GCD-GTMAC2 (10.8 and 32.4 mgkg-1), and protamine (3.0
and 9.0 mgkg-1) (A) and UFH (300 Ukg-1) followed by the injection of Dex40-GTMAC2 (12.5 mgkg-1), Dex40-GTMAC3 (7.5 mgkg-1), Dex6-GTMAC (9.6
mgkg-1), GCD-GTMAC2 (10.8 mgkg-1), and protamine (3.0 mgkg-1) (B), a-P<0.05, b-P<0.01 vs. vehicle, Mann-Whitney test. Results are shown as mean
±SD, n = 4–6.
doi:10.1371/journal.pone.0119486.g008
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affinity of emerging IgM-class immunoglobulins in early immune response, it is possible that
weakly-binding unspecific background antibodies produced most of the ELISA signal. IgG-
class response, however, was detectable in all mice in the protamine group beginning from day
21st on. On day 36 the mean protamine-specific IgG signal in the protamine group was signifi-
cantly higher than the background signal in the UFH group (P<0.01). In contrast to this result,
no significant levels of IgG specific to Dex40-GTMAC2 and Dex40-GTMAC3 were detected
(Fig. 9). To further evaluate an immunogenic potential of the antigens tested, we measured and
weighed spleens of all animals in the immunization experiments since strong immunogens are
known to induce splenomegaly. However, no significant differences in spleen size or weight
were detected in any of the experimental groups.
Discussion
The main goal of the study presented in this paper was to search for a new UFH antidote that
would be safer than protamine, while having similar antiheparin potency. Among fourteen ini-
tially synthesized cationic derivatives of polysaccharides with various structures (both linear
and cyclic), molecular weights (from 1 up to 200 kDa), and charge densities (degree of substitu-
tion with cationic groups ranging from 0.1 to more than 4), using in vitro and in vivo assays we
found the most potent and the safest one.
Present work is a continuation of our previous studies on dextran and hydroxypropylcellu-
lose, and included two new polysaccharides, i.e., pullulan and γ-cyclodextrin, while we discon-
tinued experiments on chitosan-based polymer. We disqualified some of the obtained
polysaccharides at a quite early stage of the studies. One polymer was poorly soluble (Dex40-
PAH), while five others (Dex1-GTMAC, Dex40-GTMAC1, Dex40-APTMAC,
GCD-GTMAC1, and HPC-APTMAC1) lacked in vitro UFH binding activity, the property we
Fig 9. Evaluation of the immune response to the cationic polymers.Humoral immune response
evaluation by ELISA on day 36 of the experiment. The levels of IgG specific toward different UFH inhibitors in
individual mice presented as values of absorbance in ELISA test. The inserted graph shows mean ELISA
signals corresponding to the levels of anti-protamine-, anti-Dex40-GTMAC2- or Dex40-GTMAC3-IgG present
in sera of mice immunized with matching UFH-antidotes (gray bars) compared to the signals from sera of
control mice treated with UFH alone (black bars). All sera applied in 1:100 dilution, b-P<0.01, Mann-Whitney
test. Results are shown as mean ± SD, n = 5.
doi:10.1371/journal.pone.0119486.g009
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considered a prerequisite, probably due to low cationic charge density. The remaining eight
polymers, all of which successfully passed in vitro tests, were qualified for further experiments.
We found that four of them (Dex40-Spm, Dex40-PAH-Arg, Pul-GTMAC and HPC-APT-
MAC2) were lethal or extremely hypotensive at the preliminary stages of the in vivo study, thus
experiments on those derivatives were discontinued to reduce the number of scarified animals
according the 3R rule. Finally, we evaluated in vivo four polymers: Dex6-GTMAC,
Dex40-GTMAC2, Dex40-GTMAC3, and GCD-GTMAC2. Among them the performance of
Dex40-GTMAC2 was the poorest. When administered in non-hypotensive dose, it did not in-
hibit anticoagulatory and antithrombotic activity of UFH, although it lacked immunogenicity.
All three remaining polymers significantly reversed action of UFH. We expected good efficacy
in the case of Dex40-GTMAC3, as we had previously found partial antiheparin activity of a
similar, but less cationic, 40 kDa dextran [17]. The results with GCD-GTAC2 were also not
surprising, since others showed that a cationic polymer with a cyclic structure (PM102) suc-
cessfully binds heparins [31] and a β-cyclodextrin-containing polycation neutralizes anionic
aptamer-based anticoagulants [32]. However, the heparin reversal property of Dex6-GTMAC
was unexpected and here we report for the first time strong antiheparin activity of a low molec-
ular weight (6 kDa) cationic dextran.
Among these three promising polymers, we found that Dex40-GTMAC3 is the most potent
and the safest antidote of UFH. Unlike Dex40-GTMAC3, Dex6-GTMAC decreased, and
GCD-GTMAC increased red blood cell count, hematocrit and hemoglobin values. Dex6-GT-
MAC was hypotensive when administered in efficient antiheparin dose together with UFH.
Similarly to others [32], we observed increase of MBP after intravenous injection of cationic
β-cyclodextrin, alone or with UFH. In contrast, all hematological and hemodynamic values of
animals receiving Dex40-GTMAC3 remained within error of their baseline level. Only
Dex40-GTMAC3 and protamine comparably and fully restored the parameters of the throm-
bosis development, i.e., thrombus weight and bleeding time, and typical measures of heparins
action, i.e., aPTT and anti-fXa activity, to control values. Moreover, Dex40-GTMAC3 did not
elicit a detectable humoral immune response at doses that allow for complete neutralisation of
UFH. The heparinisation/neutralisation regimen in BALB/c mice was repeated 5 times, once
every week. This was aimed to mimic the clinical situation of dialysis patients, who are exposed
to frequent heparin administration and reversal. In contrast, protamine—even if used at lower
doses than Dex40-GTMAC3—was immunogenic in all animals and induced strong IgG re-
sponses. While this difference in immunogenic potential may be caused by the very chemical
nature of the reversal agents (protein vs. polysaccharide), it can have significant clinical impli-
cations if the novel heparin reversal agents are to be used in medical practice.
According to summary of product characteristics, 300 Ukg-1 b.w. of UFH is a maximal sin-
gle dose used during cardiopulmonary bypass, thus higher dose of UFH may be considered as
overdose. In order to simulate emergency or overdosage of UFH we administered a dose of 3 x
300 Ukg-1 b.w. We found that Dex40-GTMAC3 again completely reversed antithrombotic
and anticoagulant activity of UFH. It is known that protamine administered in doses exceeding
the ratio of 1 mg per 100 U of UFH may exert anticoagulant activity [30]. We found that
Dex40-GTMAC3 administered alone to rat in dose of 7.5 mgkg-1 b.w. clinically insignificantly
prolonged aPTT, without changing of thrombus weight, bleeding time and blood pressure.
However, the results of in vitro aPTT assay (2 x aPTT prolongation at concentration of 100
mgl-1) and the blood pressure measurement (37 mmHg decrease caused by Dex40-GTMAC3
administered in dose of 22.5 mgkg-1 b.w.) indicated that, similarly to protamine, significant ex-
ceeding the ratio of 2.5 mgkg-1 b.w. of Dex40-GTMAC3 per 100 U of UFH could not be well
tolerated by patients. It seems that positively charged compounds at high concentrations
(higher than therapeutic) exert antithrombotic activity themselves, and the mechanism could
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be associated with their hypotensive activity. Nevertheless, in contrast to delparantag—a novel,
very promising reversal agent of UFH/low molecular weight heparin/pentasaccharide, in case
of which the enrolment to clinical trial was stopped because of significant hypotension [9],
Dex40-GTMAC3 is normotensive in therapeutic doses.
The interspecies differences between rodents and human can often be a reason of drug dis-
covery failure. They are even more important in the evaluation of agents used in the treatment
of complex haemostasis and hemodynamic disorders. To make the data on the inhibition of
antithrombotic activity of UFH more meaningful we also examined the efficacy of the
Dex40-GTMAC3 in mice using a model of thrombosis in which the lesion was produced inside
abdominal vein, simulating contact of blood with thrombogenic surface [27]. Moreover, in this
model the time of observation was extended to 6 hours to be closer to long open
heart surgeries.
In contrast to many studies focusing on heparin-binding properties of protamine alterna-
tives, for example lactoferrin [33], methylene blue, vancomycin, hexadimethrine bromide [34],
or chemically-modified inactive antithrombin [35], Dex40-GTMAC3 efficacy was confirmed
in vitro and in vivo in both mice and rats. Nevertheless, we are aware that further primate stud-
ies and clinical trial are required to confirm efficacy and safety in humans. Several UFH anti-
dotes that had been promising in vitro failed at the later stages of development. For example,
the recombinant human fVIIa given to patients increased the incidence of venous thromboem-
bolism, pulmonary embolism, and myocardial infarction [36]. Platelet factor 4 as heparin anti-
dote did not complete clinical trial, probably due to safety reasons (it increases the risk of
heparin-induced thrombocytopenia) [37,38].
In agreement with other reports [39], we found that protamine is immunogenic, whereas
Dex40-GTMAC3 is not. This is an important advantage of Dex40-GTMAC3 over the prot-
amine and alternative UHF reversal agents. Other protein-based antidotes, such as heparinase
I [40], lactoferrin [33], or low molecular weight protamine [41,42] may induce immunogenic
responses similar to protamine. Moreover, availability of Dex40-GTMAC3 does not depend on
natural fish sources, which is the case of protamine sulfate. Lack of detectable immune re-
sponse towards Dex40-GTMAC3 indicates that, in contrast to protamine, it could be safely ad-
ministered to patients with fish allergy and to diabetics treated with protamine insulin.
It was suggested that some complications of cardiopulmonary bypass, such as bleeding or
thrombotic risk, thrombocytopenia, or neurological disorders [43–46] could be related to ad-
ministration of high doses of protamine [47]. However, it is very hard to separate effects of
protamine treatment from those related to the use of cardiopulmonary bypass in clinical stud-
ies. Our experimental study to some extent supplements incomplete preclinical safety profile of
protamine, pointing on its hypotensive and immunogenic properties.
Many polymers in our study were excluded during in vitro screening phase or after injection
to just a few animals due to their toxicity. We showed here these negative data, because they
may be valuable for others to exclude these compounds from their in vivo studies, even in dif-
ferent areas of application. For example, cationic polymers have been applied as gene carriers
in nonviral gene therapy [48] and as drug delivery systems [49]; their potential use as antican-
cer drugs has also been suggested [50]. Moreover, a hydrogel containing GTMAC-modified
polysaccharide can be applied to cell encapsulation and protein delivery [51,52]. Based on our
results we can claim that high molecular weight linear polymers perform better as therapeutics
than the cyclic or low molecular weight cationic polysaccharides.
We are aware that approving a first-in-man study will require not only pharmacodynamics
and general safety data, but also pharmacokinetics, organ distribution and toxicity studies. The
results may exclude Dex40-GTMAC3 from further development, thus we keep searching for
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agents in different polymer classes. We have recently shown that polyallylamine containing ar-
ginine moieties (PAH-ARG) could be a promising agent neutralizing protamine [23].
In conclusion, our team developed a novel, potent and safe heparin antidote—Dex40-GT-
MAC3, a 40 kDa dextran substituted with 0.65 GTMAC groups per a glucose unit on the aver-
age. Basing on our non-clinical evaluation of Dex40-GTMAC3 and taking into account the
preclinical registration data and clinical safety literature of protamine, we believe that the novel
polymer has very promising properties and can potentially substitute protamine as the
UFH antidote.
Supporting Information
S1 File. Synthesis of polymers.
(PDF)
S2 File. Characteristics of the polymers.
(PDF)
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